BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30563349)

  • 1. Do We Need Potent Intravenous Antiplatelet Inhibition at the Time of Reperfusion During ST-Segment Elevation Myocardial Infarction?
    Allencherril J; Alam M; Levine G; Jneid H; Atar D; Kloner RA; Birnbaum Y
    J Cardiovasc Pharmacol Ther; 2019 May; 24(3):215-224. PubMed ID: 30563349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel.
    van Leeuwen MAH; van der Hoeven NW; Janssens GN; Everaars H; Nap A; Lemkes JS; de Waard GA; van de Ven PM; van Rossum AC; Ten Cate TJF; Piek JJ; von Birgelen C; Escaned J; Valgimigli M; Diletti R; Riksen NP; van Mieghem NM; Nijveldt R; van Royen N
    Circulation; 2019 Jan; 139(5):636-646. PubMed ID: 30586720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet inhibition to target reperfusion injury trial: Rationale and study design.
    Bulluck H; Chan MHH; Bryant JA; Chai P; Chawla A; Chua TS; Chung YC; Fei G; Ho HH; Ho AFW; Hoe AJ; Imran SS; Lee CH; Lim SH; Liew BW; Yun PLZ; Hock MOE; Paradies V; Roe MT; Teo L; Wong AS; Wong E; Wong PE; Watson T; Chan MY; Tan JW; Hausenloy DJ
    Clin Cardiol; 2019 Jan; 42(1):5-12. PubMed ID: 30421441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-Year Survival After ST-Segment-Elevation Myocardial Infarction in Relation With Prehospital Administration of Dual Antiplatelet Therapy.
    Danchin N; Puymirat E; Cayla G; Cottin Y; Coste P; Gilard M; Goldstein P; Braun F; Belle L; Montalescot G; Ferrières J; Schiele F; Simon T;
    Circ Cardiovasc Interv; 2018 Sep; 11(9):e007241. PubMed ID: 30354592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon.
    Allencherril J; Jneid H; Atar D; Alam M; Levine G; Kloner RA; Birnbaum Y
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):589-597. PubMed ID: 31418141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial.
    Berger JS; Roe MT; Gibson CM; Kilaru R; Green CL; Melton L; Blankenship JD; Metzger DC; Granger CB; Gretler DD; Grines CL; Huber K; Zeymer U; Buszman P; Harrington RA; Armstrong PW
    Am Heart J; 2009 Dec; 158(6):998-1004.e1. PubMed ID: 19958867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H²⁴ Analysis.
    Montalescot G; van 't Hof AW; Bolognese L; Cantor WJ; Cequier A; Chettibi M; Collet JP; Goodman SG; Hammett CJ; Huber K; Janzon M; Lapostolle F; Lassen JF; Licour M; Merkely B; Salhi N; Silvain J; Storey RF; Ten Berg JM; Tsatsaris A; Zeymer U; Vicaut E; Hamm CW;
    JACC Cardiovasc Interv; 2016 Apr; 9(7):646-56. PubMed ID: 26952907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Aitmokhtar O; Paganelli F; Benamara S; Azaza A; Bonello L; Hamza O; Seddiki S; Benathmane T; Saidane M; Bouzid A; Kara M; Sik A; Azzouz A; Harbi F; Monsuez JJ; Benkhedda S
    Arch Cardiovasc Dis; 2017 Nov; 110(11):626-633. PubMed ID: 28583820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction.
    Chakrabarti AK; Feeney K; Abueg C; Brown DA; Czyz E; Tendera M; Janosi A; Giugliano RP; Kloner RA; Weaver WD; Bode C; Godlewski J; Merkely B; Gibson CM
    Am Heart J; 2013 Apr; 165(4):509-514.e7. PubMed ID: 23537966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a combination of antiplatelet and antithrombotic pretreatment on myocardial perfusion in patients with an acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention.
    Prech M; Bartela E; Janus M; Jeremicz I; Araszkiewicz A; Urbanska L; Pyda M; Grajek S
    Coron Artery Dis; 2016 Nov; 27(7):580-5. PubMed ID: 27228184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological prevention of reperfusion injury in acute myocardial infarction. A potential role for adenosine as a therapeutic agent.
    Quintana M; Kahan T; Hjemdahl P
    Am J Cardiovasc Drugs; 2004; 4(3):159-67. PubMed ID: 15134468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction).
    Pu J; Ding S; Ge H; Han Y; Guo J; Lin R; Su X; Zhang H; Chen L; He B;
    Circulation; 2017 Oct; 136(16):1462-1473. PubMed ID: 28844990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment with dual antiplatelet therapy in patients with ST-elevation myocardial infarction.
    Yudi MB; Farouque O; Andrianopoulos N; Ajani AE; Brennan A; Lefkovits J; Reid CM; Chan W; Duffy SJ; Clark DJ;
    Catheter Cardiovasc Interv; 2018 Aug; 92(2):E98-E105. PubMed ID: 28963757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive Assessment of the Coronary Microcirculation in Reperfused ST-Segment-Elevation Myocardial Infarction Patients: Where Do We Stand?
    Bulluck H; Foin N; Tan JW; Low AF; Sezer M; Hausenloy DJ
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28242607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis.
    Niu X; Zhang J; Bai M; Peng Y; Sun S; Zhang Z
    BMC Cardiovasc Disord; 2018 Jan; 18(1):3. PubMed ID: 29320987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracoronary or intravenous abciximab after aspiration thrombectomy in patients with STEMI undergoing primary percutaneous coronary intervention.
    Bedjaoui A; Allal K; Lounes MS; Belhadi CE; Mekarnia A; Sediki S; Kara M; Azaza A; Monsuez JJ; Benkhedda S
    Cardiovasc J Afr; 2019 Jan/Feb 23; 30(1):45-51. PubMed ID: 30460974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Capranzano P; Capodanno D; Bucciarelli-Ducci C; Gargiulo G; Tamburino C; Francaviglia B; Ohno Y; La Manna A; Antonella S; Attizzani GF; Angiolillo DJ; Tamburino C
    Eur Heart J Acute Cardiovasc Care; 2016 Sep; 5(5):475-86. PubMed ID: 26758542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction: The BVS STEMI STRATEGY-IT Study.
    Ielasi A; Campo G; Rapetto C; Varricchio A; Cortese B; Brugaletta S; Geraci S; Vicinelli P; Scotto di Uccio F; Secco GG; Poli A; Nicolini E; Ishida K; Latib A; Tespili M
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1855-1864. PubMed ID: 28935077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Valgimigli M; Campo G; Malagutti P; Anselmi M; Bolognese L; Ribichini F; Boccuzzi G; de Cesare N; Rodriguez AE; Russo F; Moreno R; Biondi-Zoccai G; Penzo C; Díaz Fernández JF; Parrinello G; Ferrari R
    JACC Cardiovasc Interv; 2011 Jan; 4(1):51-62. PubMed ID: 21251629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between gender and short-term outcome in patients with ST elevation myocardial infraction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis.
    Venetsanos D; Sederholm Lawesson S; Alfredsson J; Janzon M; Cequier A; Chettibi M; Goodman SG; Van't Hof AW; Montalescot G; Swahn E
    BMJ Open; 2017 Sep; 7(9):e015241. PubMed ID: 28939567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.